EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Epigenetically controlled endothelial promyelocytic leukemia drives liver inflammation and fibrosis

Can Gan, Enjiang Lai, Yang Tai, Shuai Chen, Chong Zhao, Wenting Dai, Zhu Yang, Bei Li, Tian Lan, Yang Xiao, Yangkun Guo, Jiaxin Chen und 11 weitere

Journal of Clinical Investigation · 01.06.2026 · 136 (11)

DOI: 10.1172/jci196730 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 17.03.2026. Verfasst von Can Gan und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Lab of Gastroenterology and Hepatology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, …. Hauptthemen laut MEDLINE: Liver Cirrhosis, Epigenesis, Genetic, Promyelocytic Leukemia Protein, Transcription Factors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAAA NIH HHS, the National Natural Science Fund of China, the National Key R&D Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cellular and molecular heterogeneity in the liver has been increasingly recognized to drive liver fibrosis progression, but the particular events that occur initially in response to liver injury and trigger immune cell recruitment remain unclear. Here, we identify epigenetically aberrant liver sinusoidal endothelial cells (LSECs) as key players in this process. Mechanistically, the epigenetic readers like bromodomain-containing protein 4–dependent (BRD4-dependent) super enhancers (SEs) activate proinflammatory genes, including promyelocytic leukemia (PML). The PML protein, in turn, binds BRD4 and amplifies proinflammatory angiocrine signaling through phase separation–dependent SE activation via PML/BRD4 condensate formation. In mouse models, LSEC-specific depletion of the PML/BRD4 complex mitigates liver inflammation and fibrosis. Single-cell RNA-seq reveals that epigenetically aberrant LSECs exhibit a reprogrammed proinflammatory angiocrine landscape in mouse fibrotic livers. TIMP1 + LSECs promote the recruitment of CD63 + monocyte–derived macrophages (MoMFs) during liver fibrosis progression. Thereby, PML/BRD4 in LSECs governs inflammatory immune cell recruitment in liver fibrosis. Pharmacological BRD4 inhibition or epigenetic PML-SE repression alleviates liver inflammation and fibrosis. In conclusion, PML/BRD4-mediated SE activation via phase separation drives proinflammatory angiocrine signaling in LSECs, initiating the inflammatory cascade and subsequent immune cell recruitment during liver fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisEpigenesis, GeneticPromyelocytic Leukemia ProteinTranscription FactorsEndothelial CellsHepatitisAnimalsBromodomain Containing ProteinsHumansMiceCell Cycle ProteinsSuper EnhancersNuclear Proteins

Stichwörter der Autor:innen

Endothelial cellsEpigeneticsFibrosisGastroenterologyHepatology

Substanzen

Bromodomain Containing ProteinsPromyelocytic Leukemia ProteinTranscription FactorsBrd4 protein, mouseCell Cycle ProteinsBRD4 protein, humanPml protein, mousePML protein, humanNuclear Proteins

Autor:innen und Institutionen

  • Department of Gastroenterology, Lab of Gastroenterology and Hepatology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Gastroenterology and Hepatology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Department of Biliary Surgery, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • The First Affiliated Hospital, Key Laboratory of Regenerative Medicine of Ministry of Education, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong, China.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Förderung

  • NIAAA NIH HHS
  • the National Natural Science Fund of China
  • the National Key R&D Program of China
  • the 135 projects for disciplines of excellence of West China Hospital, Sichuan University
  • the Postdoctor Research Fund of West China Hospital, Sichuan University
  • the International Science & Technology Cooperation Project of Sichuan
  • the Sichuan Science and Technology Program
  • the Shenzhen Medical Research Funds

Zitieren

APA

Gan, C., Lai, E., Tai, Y., Chen, S., Zhao, C., Dai, W., Yang, Z., Li, B., Lan, T., Xiao, Y., Guo, Y., Chen, J., Wei, B., Che, Z., Cao, S., Liu, M., Tacke, F., Tang, C., Shah, V. H., …, & Gao, J. (2026). Epigenetically controlled endothelial promyelocytic leukemia drives liver inflammation and fibrosis. Journal of Clinical Investigation, 136(11). https://doi.org/10.1172/jci196730

Vancouver

Gan C, Lai E, Tai Y, Chen S, Zhao C, Dai W, et al. Epigenetically controlled endothelial promyelocytic leukemia drives liver inflammation and fibrosis. Journal of Clinical Investigation. 2026;136(11). doi:10.1172/jci196730

BibTeX
@article{Gan2026,
  author = {Gan, Can and Lai, Enjiang and Tai, Yang and Chen, Shuai and Zhao, Chong and Dai, Wenting and Yang, Zhu and Li, Bei and Lan, Tian and Xiao, Yang and Guo, Yangkun and Chen, Jiaxin and Wei, Bo and Che, Zhaodi and Cao, Sheng and Liu, Mengfei and Tacke, Frank and Tang, Chengwei and Shah, Vijay H and Yu, Haopeng and Wang, Fei and Huang, Zhiyin and Gao, Jinhang},
  title = {Epigenetically controlled endothelial promyelocytic leukemia drives liver inflammation and fibrosis},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {11},
  doi = {10.1172/jci196730}
}
Kostenlos starten →